Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKL-PSY
- Development stage
- Unknown
- Lead developer
- SK Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**SKL-PSY** is a novel small molecule developed by SK Biopharmaceuticals for the treatment of depression and bipolar disorder. It demonstrates a rapid onset of therapeutic effects in animal models of depressive and manic states, potentially addressing limitations of current antidepressants that require 2-4 weeks for efficacy. The drug is designed to be effective for both manic and depressive phases of bipolar disorder, with preclinical development supported by collaborations in China, and it is currently advancing toward clinical evaluation in psychiatric indications.[2][6][11]
- Other names
- SK-PSY
Beyond the preview
Go deeper on SKL-PSY.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SKL-PSY.